ClinicalTrials.gg
CompletedNCT00654082Updated Feb 1, 2021

A Study Evaluating the Efficacy and Safety of Sildenafil in Men With Traumatic Spinal Cord Injury and Erectile Dysfunction

A Phase 4 interventional study of sildenafil and placebo in Spinal Cord Injury, Erectile Dysfunction and Spinal Cord Trauma, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 5 sites in Turkey. Open to male participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
19 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 62 studies in Spinal Cord Injuries with a site in Turkey — 16 open to participants now, 18 under way, 1 of them phase 3. Spinal Cord Injuries · Turkey.

Enrollment
2nd of 31
88 · median 34
Started
2002
the only one that year
Phase 4
Only one
of the 62
Registered
1st of 62
by date

Among the 62 studies in Spinal Cord Injuries with a site in Turkey, this one is the 2nd largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2002, is the only one in phase 4, and was the 1st registered.

Spinal Cord Injuries

2,028 studies on the registry are indexed under Spinal Cord Injuries; 540 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

16 of the 62 studies in Spinal Cord Injuries with a site in Turkey are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 376 Spinal Cord Injuries studies recruiting now, 167 (44%) set no upper age limit and 158 (42%) stop at 75 or younger; 41 take children under 18; 52 take healthy volunteers.

This study: 19 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Spinal Cord Injuries with a site in Turkey, or all of them as a file.
02

Study summary

To demonstrate the efficacy, safety and tolerability of sildenafil administered orally, as required, approximately 1 hour prior to sexual activity to men with erectile dysfunction (ED) associated with spinal cord injury (SCI), as well as its effects on the quality of life (QoL) of these patients.

03

Conditions studied

  • Spinal Cord Injury
  • Erectile Dysfunction
  • Spinal Cord Trauma
  • Injuries, Spinal Cord
  • Impotence
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Patients were men with spinal cord injury and erectile dysfunction

Exclusion criteria

Exclusion Criteria:

-N/A

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
88 participants (actual)

Study arms

  • Active comparator
    Arm 1

    Drug: sildenafil

  • Placebo comparator
    Arm 2

    Drug: placebo

Interventions

  • sildenafil 50 mg tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks; after 2 weeks on treatment, doses could be escalated to 100 mg or reduced to 25 mg

  • Drugplacebo

    placebo tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks

06

What researchers measure

Primary outcomes

  1. The proportion of subjects who indicated a preference for either treatment and who said that the treatment improved their erections

    Time frame: Weeks 6 and 14

Secondary outcomes

  1. Responses to the International Index of Erectile Function (IIEF)

    Time frame: Weeks 0, 6, 8, and 14

  2. Responses to the Global Efficacy Assessment (GEA) Question

    Time frame: Weeks 0, 6, 8, and 14

  3. Responses to questions on the Quality of Life (QoL) Questionnaire

    Time frame: Weeks 0, 6, 8, and 14

  4. Responses to Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questions

    Time frame: Weeks 0, 6, 8, and 14

  5. Intercourse success rate derived from patient event log

    Time frame: Weeks 0, 6, 8, and 14

07

Study locations

5 sites
  • Pfizer Investigational Site
    Bahcelievler, Istanbul 34580, Turkey
  • Pfizer Investigational Site
    Balcova, Izmir, Turkey
  • Pfizer Investigational Site
    Ankara, Turkey
  • Pfizer Investigational Site
    Bursa, Turkey
  • Pfizer Investigational Site
    Konya, Turkey
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2002 and a completion of Aug 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2008
First posted
Apr 7, 2008
Start
Sep 2002
CompletionActual
Aug 2003
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00654082
Responsible party
Sponsor
First posted
Apr 7, 2008
Start date
Sep 2002
Completion
Aug 2003
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion